Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial

Show other versions (1)

Background: COIN compared first-line continuous chemotherapy with the same chemotherapy given intermittently or with cetuximab in advanced colorectal cancer (aCRC). Methods: Choice between oxaliplatin/capecitabine (OxCap) and oxaliplatin/leucovorin (LV)/infusional 5-FU (OxFU) was by physician and pa...

Full description

Bibliographic Details
Main Authors:	Madi, A, Fisher, D, Wilson, R, Adams, R, Meade, A, Kenny, S, Nichols, L, Seymour, M, Wasan, H, Kaplan, R, Maughan, T
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
by: Madi, A, et al.
Published: (2012)

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL
by: Madi, A, et al.
Published: (2010)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
by: Adams, R, et al.
Published: (2009)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
by: Adams, R, et al.
Published: (2010)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
by: Adams, R, et al.
Published: (2009)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
by: Maughan, T, et al.
Published: (2010)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
by: Maughan, T, et al.
Published: (2009)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
by: Adams, R, et al.
Published: (2011)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
by: Adams, R, et al.
Published: (2009)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
by: Maughan, T, et al.
Published: (2011)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
by: Taieb, J, et al.
Published: (2012)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
by: Maughan, T, et al.
Published: (2010)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
by: Ruijia Chen, et al.
Published: (2022-07-01)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
by: Wasan, H, et al.
Published: (2011)

First reported case of ANCA-associated vasculitis induced by oxaliplatin, capecitabine, and trastuzumab
by: Bengang Huo, et al.
Published: (2023-12-01)

Acute mania due to capecitabine and oxaliplatin in a patient with metastatic colorectal cancer
by: Parikshit Padhi
Published: (2023-03-01)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
by: Akihiko Hatano, et al.
Published: (2023-11-01)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
by: West, H, et al.
Published: (2018)

Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study
by: Anchuan Li, et al.
Published: (2022-07-01)

Preliminary phase IISOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (IRT) in patients (pts) with locally advanced rectal cancer (LARC).
by: Glynne-Jones, R, et al.
Published: (2004)

Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer
by: Mohammad Ali Mashhadi, et al.
Published: (2016-10-01)

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation
by: A Pandor, et al.
Published: (2006-11-01)

Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC).
by: Glynne-Jones, R, et al.
Published: (2005)

Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
by: Evans, T, et al.
Published: (2006)

Adsorption of Oxaliplatin by Hydroxyapatite
by: Papageorgiou A., et al.
Published: (2007-12-01)

Cardiotoxicity induced by capecitabine and oxaliplatin in gastric cancer treatment: a rare case of cardiac arrest and cardiogenic shock
by: Muhammad Umer Riaz Gondal, et al.
Published: (2024-03-01)

Modified biweekly oxaliplatin and capecitabine for advanced gastric cancer: A retrospective analysis from a medical center
by: Yung-Chia Kuo, et al.
Published: (2014-06-01)

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
by: Chu Matsuda, et al.
Published: (2023-01-01)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
by: Wood, G, et al.
Published: (2017)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
by: Mukherjee, S, et al.
Published: (2017)

Affinities to Oxaliplatin: Vitamins from B Group vs. Nucleobases
by: Beata Szefler, et al.
Published: (2022-09-01)

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
by: Jie Zhao, et al.
Published: (2022-10-01)

XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer
by: Ming-Yii Huang, et al.
Published: (2023-05-01)

A pilot study of the use of Oxaliplatin in metastatic colorectal cancer at Velindre
by: Mitra, S, et al.
Published: (2001)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
by: Adams, R, et al.
Published: (2008)

Oxaliplatin-Related Ocular Toxicity
by: Marina Mesquida, et al.
Published: (2010-11-01)

Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth—An Investigation of the Activation Mechanism and Their Nanoformulation
by: Carlo Marotta, et al.
Published: (2024-02-01)

Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer
by: Gray, V, et al.
Published: (2019)

NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.
by: Mukherjee, S, et al.
Published: (2015)

NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.
by: Mukherjee, S, et al.
Published: (2015)